| Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study S Sacchi, L Marcheselli, A Bari, R Marcheselli, S Pozzi, S Luminari, ... Haematologica 93 (3), 398-404, 2008 | 129 | 2008 |
| Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients S Pozzi, R Marcheselli, S Sacchi, L Baldini, F Angrilli, E Pennese, ... Leukemia & lymphoma 48 (1), 56-64, 2007 | 124 | 2007 |
| Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story A Bari, L Marcheselli, S Sacchi, R Marcheselli, S Pozzi, P Ferri, E Balleari, ... Annals of Oncology 21 (7), 1486-1491, 2010 | 120 | 2010 |
| Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population‐based analysis S Pozzi, L Marcheselli, A Bari, EV Liardo, R Marcheselli, S Luminari, ... British journal of haematology 163 (1), 40-46, 2013 | 102 | 2013 |
| Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis M Pirani, R Marcheselli, L Marcheselli, A Bari, M Federico, S Sacchi Annals of Oncology 22 (8), 1845-1858, 2011 | 96 | 2011 |
| Neutrophil‐lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving … R Marcheselli, A Bari, T Tadmor, L Marcheselli, MC Cox, S Pozzi, ... Hematological oncology 35 (4), 561-566, 2017 | 59 | 2017 |
| Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma S Sacchi, S Pozzi, R Marcheselli, M Federico, A Tucci, F Merli, L Orsucci, ... Cancer 110 (1), 121-128, 2007 | 57 | 2007 |
| Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma L Marcheselli, R Marcheselli, A Bari, EV Liardo, F Morabito, L Baldini, ... Leukemia & lymphoma 52 (10), 1867-1872, 2011 | 54 | 2011 |
| Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. S Pozzi, R Marcheselli, S Sacchi, G Quarta, P Musto, G Caparrotti, ... Blood 106 (11), 5057, 2005 | 50 | 2005 |
| Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study S Sacchi, L Marcheselli, A Bari, R Marcheselli, S Pozzi, PG Gobbi, ... haematologica 93, 1335-1342, 2008 | 47 | 2008 |
| Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide AJ Yee, P Hari, R Marcheselli, AK Mahindra, DD Cirstea, TA Scullen, ... British journal of haematology 166 (3), 401-409, 2014 | 43 | 2014 |
| A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem … S Sacchi, R Marcheselli, A Lazzaro, F Morabito, A Fragasso, ND Renzo, ... Leukemia & lymphoma 52 (10), 1942-1948, 2011 | 37 | 2011 |
| Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study R Marcheselli, L Marcheselli, L Cortesi, A Bari, C Cirilli, S Pozzi, P Ferri, ... Journal of Breast Cancer 18 (4), 378, 2015 | 34 | 2015 |
| Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy C Baldessari, G Guaitoli, F Valoriani, R Bonacini, R Marcheselli, ... Clinical Nutrition ESPEN 43, 64-75, 2021 | 22 | 2021 |
| Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione … S Sacchi, R Marcheselli, A Bari, G Buda, AL Molinari, L Baldini, D Vallisa, ... haematologica 101 (5), e196, 2016 | 19 | 2016 |
| The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments A Bari, R Marcheselli, S Sacchi, A Re, C Pagani, A Tucci, B Botto, U Vitolo, ... Annals of Hematology 99, 277-282, 2020 | 15 | 2020 |
| Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase … S Pozzi, M Gentile, S Sacchi, R Marcheselli, A Corso, F Cocito, P Musto, ... Leukemia & Lymphoma 58 (3), 552-559, 2017 | 15 | 2017 |
| Prevalence and prognostic significance of sMUC‐1 levels in plasma cell dyscrasias S Luminari, M Goldaniga, F Ceccherelli, A Guffanti, E Bombardieri, ... British journal of haematology 121 (5), 772-774, 2003 | 14 | 2003 |
| Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors A Bari, L Marcheselli, R Marcheselli, EV Liardo, S Pozzi, P Ferri, S Sacchi Mediterranean Journal of Hematology and Infectious Diseases 3 (1), 2011 | 13 | 2011 |
| Gruppo Italiano Studio Linfomi. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients S Pozzi, R Marcheselli, S Sacchi, L Baldini, F Angrilli, E Pennese, ... Leuk Lymphoma 48 (1), 56-64, 2007 | 11 | 2007 |
